OVID OVID THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, OVID THERAPEUTICS INC reported revenue of $733K (down 88.3% from a year earlier), net income of −$15.0M and diluted EPS of n/a; over the last four quarters revenue was $1.58M and net income −$34.5M; for the fiscal year ended December 2025 revenue was $7.25M, up 1181.3% on the year before.
OVID annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $7.25M, gross profit n/a, operating income −$42.4M, net income −$17.4M (margin -239.9%), EPS n/a
- Fiscal year ended Dec 2024: revenue $566K, gross profit n/a, operating income −$61.9M, net income −$26.4M (margin -4664.3%), EPS n/a
- Fiscal year ended Dec 2023: revenue $392K, gross profit n/a, operating income −$59.3M, net income −$52.3M (margin -13341.8%), EPS −$0.74
- Fiscal year ended Dec 2022: revenue $1.50M, gross profit n/a, operating income −$55.5M, net income −$54.2M (margin -3604.7%), EPS −$0.77
- Fiscal year ended Dec 2021: revenue $208M, gross profit n/a, operating income $124M, net income $123M (margin 58.9%), EPS $1.76
OVID quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $733K (down 88.3% year over year), net income −$15.0M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$17.0M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $718K (up 844.7% year over year), net income $9.68M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $132K (down 23.7% year over year), net income −$12.2M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $6.27M (up 3611.2% year over year), net income −$4.68M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $130K (down 12.2% year over year), net income −$10.2M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $76.0K (down 46.5% year over year), net income −$9.22M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $173K (up 58.7% year over year), net income −$14.0M, EPS −$0.20
- Quarter ended Jun 30, 2024: revenue $169K (up 125.3% year over year), net income $8.52M, EPS $0.12
- Quarter ended Mar 31, 2024: revenue $148K (up 124.2% year over year), net income −$11.7M, EPS −$0.17
- Quarter ended Dec 31, 2023 (from the annual report): revenue $142K (up 206.8% year over year), net income −$15.3M, EPS −$0.21
- Quarter ended Sep 30, 2023: revenue $109K (up 881.8% year over year), net income −$11.3M, EPS −$0.16
- Quarter ended Jun 30, 2023: revenue $75.0K, net income −$12.4M, EPS −$0.18
- Quarter ended Mar 31, 2023: revenue $66.0K (down 95.4% year over year), net income −$13.4M, EPS −$0.19
- Quarter ended Dec 31, 2022 (from the annual report): revenue $46.3K, net income −$11.5M, EPS −$0.16
- Quarter ended Sep 30, 2022: revenue $11.1K, net income −$12.0M, EPS −$0.17
- Quarter ended Jun 30, 2022: revenue $0, net income −$14.6M, EPS −$0.21
- Quarter ended Mar 31, 2022: revenue $1.45M (down 99.3% year over year), net income −$16.1M, EPS −$0.23
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$26.0M, EPS −$0.37
- Quarter ended Sep 30, 2021: revenue $0, net income −$11.4M, EPS −$0.17
OVID cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$38.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$56.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$45.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$55.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $119M, share buybacks n/a
OVID balance sheet
- Jun 30, 2026: cash $11.3M, total assets $232M, total liabilities $22.1M, shareholders' equity $210M
- Mar 31, 2026: cash $94.1M, total assets $226M, total liabilities $27.4M, shareholders' equity $198M
- Dec 31, 2025: cash $13.2M, total assets $151M, total liabilities $20.3M, shareholders' equity $131M
- Sep 30, 2025: cash $20.6M, total assets $63.8M, total liabilities $19.2M, shareholders' equity $44.7M
- Jun 30, 2025: cash $28.4M, total assets $77.4M, total liabilities $21.6M, shareholders' equity $55.8M
- Mar 31, 2025: cash $21.1M, total assets $81.7M, total liabilities $22.4M, shareholders' equity $59.3M
- Dec 31, 2024: cash $26.3M, total assets $92.2M, total liabilities $23.9M, shareholders' equity $68.2M
- Sep 30, 2024: cash $15.0M, total assets $103M, total liabilities $26.4M, shareholders' equity $76.3M
What is OVID's revenue?
OVID THERAPEUTICS INC reported $1.58M of revenue over its last four quarters, through June 30, 2026.
Is OVID profitable?
No. OVID THERAPEUTICS INC lost $34.5M over the last four quarters.